Extrapolating upon this, leuco-methylthioninium bis (hydromethanesulphonate) or LMTM is an oxidized form of this methylthioninium moiety that is being developed as a treatment for AD based on inhibition of tau aggregation. The gene discussed is MAPT; the disease is Alzheimer disease.